Press coverage about Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Tonix Pharmaceuticals Holding Corp. earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.0247984083549 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:
- Are Investors Shying Away from Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)? – FLBC News (flbcnews.com)
- Tonix Pharmaceuticals Holding Corp. (TNXP) CEO Buys $60,000.00 in Stock (americanbankingnews.com)
- Tonix Pharmaceuticals Holding Corp. (TNXP) Upgraded to Buy by Roth Capital (americanbankingnews.com)
- Tonix Pharmaceuticals Holding Corp. (TNXP) noted a price change of -8.95% and Fonar Corporation (FONR) closes … – Stocks Gallery (stocksgallery.com)
- Watching the Tape Move for Tonix Pharmaceuticals Holding Corp (TNXP) – Sparta Review (spartareview.com)
Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) traded down 0.67% during midday trading on Friday, reaching $2.95. 252,628 shares of the company’s stock traded hands. Tonix Pharmaceuticals Holding Corp. has a 52-week low of $0.33 and a 52-week high of $9.40. The firm’s market capitalization is $22.15 million. The stock’s 50 day moving average price is $3.87 and its 200 day moving average price is $3.29.
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) last released its quarterly earnings results on Monday, August 14th. The company reported ($0.65) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.78) by $0.13. On average, equities research analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post ($3.16) EPS for the current fiscal year.
A number of equities research analysts recently weighed in on the stock. Roth Capital upgraded shares of Tonix Pharmaceuticals Holding Corp. from a “neutral” rating to a “buy” rating and set a $6.00 price objective on the stock in a research note on Friday. They noted that the move was a valuation call. Aegis began coverage on shares of Tonix Pharmaceuticals Holding Corp. in a research note on Monday, June 26th. They set a “buy” rating and a $10.00 price objective on the stock.
TRADEMARK VIOLATION WARNING: “Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Receives Media Impact Rating of 0.16” was published by BNB Daily and is the property of of BNB Daily. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.baseball-news-blog.com/2017/08/19/tonix-pharmaceuticals-holding-corp-nasdaqtnxp-receives-daily-media-impact-score-of-0-16-updated.html.
In related news, Director Ernest Mario sold 6,105 shares of the stock in a transaction dated Friday, June 30th. The stock was sold at an average price of $4.28, for a total transaction of $26,129.40. Following the completion of the transaction, the director now directly owns 63,073 shares in the company, valued at $269,952.44. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Seth Lederman acquired 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 20th. The shares were purchased at an average price of $4.22 per share, with a total value of $84,400.00. Following the completion of the acquisition, the chief executive officer now owns 7,912 shares of the company’s stock, valued at approximately $33,388.64. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 50,000 shares of company stock worth $188,050. 4.00% of the stock is currently owned by insiders.
About Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The companys lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.
Receive News & Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related companies with MarketBeat.com's FREE daily email newsletter.